TY - JOUR
T1 - Leveraging Hypomethylating Agents for Better MDS Therapy
AU - Bradley, Terrence J.
AU - Watts, Justin M.
AU - Swords, Ronan T.
N1 - Publisher Copyright:
© 2018, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Purpose of Review: Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. New therapies to improve outcomes are urgently needed. Recent Findings: Clinical trials combining standard hypomethylating agents with novel experimental agents are underway in an effort to improve clinical outcomes in MDS patients. Several of these small molecules have demonstrated the ability to augment the response rates of hypomethylating agents alone, including complete remission rates, in both the front line and refractory settings. Summary: Combination approaches utilizing hypomethylating agents and novel-targeted therapies have demonstrated the ability to improve response rates in MDS patients in both the front line and salvage settings, and thus may change the standard of care.
AB - Purpose of Review: Myelodysplastic syndrome (MDS) is a clinically and molecularly heterogeneous disease, which primarily occurs in older adults. Although hypomethylating agents have survival benefit and are the current standard of care, many MDS patients will not garner a response from therapy. For those who do respond, most responses are not durable, and the only hope for a cure is allogeneic stem cell transplant. New therapies to improve outcomes are urgently needed. Recent Findings: Clinical trials combining standard hypomethylating agents with novel experimental agents are underway in an effort to improve clinical outcomes in MDS patients. Several of these small molecules have demonstrated the ability to augment the response rates of hypomethylating agents alone, including complete remission rates, in both the front line and refractory settings. Summary: Combination approaches utilizing hypomethylating agents and novel-targeted therapies have demonstrated the ability to improve response rates in MDS patients in both the front line and salvage settings, and thus may change the standard of care.
KW - Acute myeloid leukemia
KW - Hypomethylating agents
KW - Immunotherapy
KW - Isocitrate dehydrogenase
KW - Myelodysplastic syndrome
KW - Pevonedistat
UR - http://www.scopus.com/inward/record.url?scp=85054330394&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054330394&partnerID=8YFLogxK
U2 - 10.1007/s11899-018-0477-3
DO - 10.1007/s11899-018-0477-3
M3 - Review article
C2 - 30267380
AN - SCOPUS:85054330394
SN - 1558-8211
VL - 13
SP - 507
EP - 515
JO - Current Hematologic Malignancy Reports
JF - Current Hematologic Malignancy Reports
IS - 6
ER -